Provention Bio Inc logo

PRVB

Provention Bio Inc

$5.06

Earnings Summary

Revenue
$0.75Mn
Net Profits
$-29.69Mn
Net Profit Margins
-3979.49%

Highlights

Revenue:

Provention Bio Inc’s revenue jumped +Inf% since last year same period to $0.75Mn in the Q2 2022. On a quarterly growth basis, Provention Bio Inc has generated 28.62% jump in its revenue since last 3-months.

Net Profits:

Provention Bio Inc’s net profit fell -1.87% since last year same period to $-29.69Mn in the Q2 2022. On a quarterly growth basis, Provention Bio Inc has generated -35.14% fall in its net profits since last 3-months.

Net Profit Margins:

Provention Bio Inc’s net profit margin jumped NaN% since last year same period to -3979.49% in the Q2 2022. On a quarterly growth basis, Provention Bio Inc has generated -5.07% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Provention Bio Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.5
EPS Estimate Current Year
-0.5

Highlights

EPS Estimate Current Quarter:

Provention Bio Inc’s earning per share (EPS) estimates for the current quarter stand at -0.5 - a -6.38% fall from last quarter’s estimates.

EPS Estimate Current Year:

Provention Bio Inc’s earning per share (EPS) estimates for the current year stand at -0.5.

Key Ratios

Key ratios of the Provention Bio Inc post its Q2 2022 earnings

Return on Assets (ROA)
-0.49
Return on Equity (ROE)
-0.88
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Provention Bio Inc’s return on assets (ROA) stands at -0.49.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Provention Bio Inc’s return on equity (ROE) stands at -0.88.

Dividend Per Share (DPS):

Provention Bio Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.47
-0.35
25.53%

Company Information

Provention Bio, Inc. is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Biologics License Application (BLA) for teplizumab, its lead investigational drug candidate, for the delay or prevention of clinical type 1 diabetes in at-risk individuals, has been filed by the U.S. Food and Drug Administration (FDA). The Company's pipeline includes additional clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in other autoimmune diseases, including celiac disease and lupus.

Organisation
Provention Bio Inc
Headquarters
Red Bank, New Jersey, US
Employees
59
Industry
Health Technology
CEO
Ashleigh Palmer